Research Disclaimer
This article reviews published scientific literature for educational purposes only. All compounds referenced are sold by Blank Peptides exclusively for in-vitro research and laboratory use. Nothing in this article constitutes medical advice, a treatment recommendation, or an endorsement of human use.
GLP-1 receptor agonists have dominated metabolic research since 2023. With three major compounds now widely available, understanding their differences is essential for designing effective protocols.
Understanding the GLP-1 Receptor System
Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by intestinal L-cells in response to food intake. It plays a central role in glucose homeostasis through several interconnected mechanisms:
- Insulin secretion: stimulates glucose-dependent insulin release from pancreatic beta cells
- Glucagon suppression reduces glucagon release, lowering hepatic glucose output
- Gastric emptying slows, which extends nutrient absorption time
- Appetite signaling: modulates hypothalamic pathways to reduce food intake
Semaglutide: The GLP-1 Selective Agonist
Semaglutide at a Glance
- Receptor profile: GLP-1 only (mono-agonist)
- Half-life: ~168 hours (7 days)
- Published efficacy: STEP trials, 15–17% mean weight reduction
- Price: $75
Semaglutide is a modified GLP-1 analog with a C-18 fatty acid chain that enables albumin binding, dramatically extending its half-life. This was the compound that catalyzed the current wave of metabolic research interest and remains the most extensively studied GLP-1 agonist.
Research Applications
- Obesity models: appetite suppression via hypothalamic signaling and delayed gastric emptying
- Type 2 diabetes, with improved insulin sensitivity and high GLP-1R selectivity
- Cardiovascular risk, with established data from large-scale clinical trials
- NASH/MAFLD: moderate impact on hepatic fat accumulation
Tirzepatide: The Dual GLP-1/GIP Agonist
Tirzepatide at a Glance
- Receptor profile: GLP-1 + GIP dual agonist (twincretin)
- Half-life: ~120 hours (5 days)
- Published efficacy: SURMOUNT trials, 20–22% mean weight reduction
- Price: $65
Tirzepatide engages both GLP-1 and GIP receptors at once, which was a first for incretin research. The GIP component adds metabolic effects that GLP-1 alone cannot achieve, particularly in fat tissue metabolism and insulin sensitivity.
Research Applications
- Advanced obesity models: the dual mechanism produces effects neither receptor achieves on its own
- Lipid metabolism, where GIP receptor activation enhances fat oxidation
- Tolerability studies, since GIP engagement appears to reduce nausea compared with pure GLP-1 agonists
- Comparative protocols: head-to-head studies against semaglutide
Retatrutide: The Triple Agonist
Retatrutide at a Glance
- Receptor profile: GLP-1 + GIP + Glucagon triple agonist
- Half-life: ~168 hours (approximately 7 days)
- Published efficacy: Phase 2 trials, up to 24% mean weight reduction
- Price: $135
Retatrutide adds a third receptor, the glucagon receptor, creating the first triple incretin agonist available for research. The glucagon component introduces direct effects on energy expenditure and hepatic lipid metabolism that dual agonists lack.
Research Applications
- NASH/MAFLD liver research: glucagon receptor activation specifically targets hepatic fat reduction
- Energy expenditure, where the glucagon component raises basal metabolic rate
- Advanced obesity models, with the highest efficacy of any incretin compound studied to date
- Multi-receptor pharmacology: the broadest receptor engagement for mechanistic studies
Head-to-Head Comparison
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptors | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Half-life | ~7 days | ~5 days | ~7 days |
| Weight Reduction | 15–17% | 20–22% | Up to 24% |
| GI Tolerability | Moderate | Better | Variable |
| Liver Fat Impact | Moderate | Moderate-High | Highest |
| Literature Base | Most extensive | Growing rapidly | Early but promising |
| Blank Price | $75 | $65 | $135 |
Which Compound Is Right for Your Research?
Quick Decision Guide
- Choose Semaglutide if your research builds on established GLP-1 protocols, requires extensive literature support, or focuses on glucose homeostasis and appetite regulation
- Choose Tirzepatide if you’re investigating additive GIP signaling effects, studying lipid metabolism, or need better tolerability for longer-duration studies
- Choose Retatrutide if your research targets hepatic steatosis, energy expenditure, or requires the broadest possible receptor engagement
All three compounds are available from Blank Peptides with full third-party COA documentation and research-grade purity verification.
Browse These Compounds
Written by Blank Peptides Research Team
Peptide science researchers with 5+ years in US-based peptide manufacturing, independent HPLC and mass spectrometry testing, and research education. All content is reviewed for scientific accuracy before publication.
REVIEWED BY
Dr. Tobias S — PhD Chemist, Peptide and Unnatural Amino Acid Synthesis
Dr. Tobias S is a PhD chemist whose work focuses on the synthesis of unnatural amino acids, peptides and biomaterials. He completed both his undergraduate chemistry studies and his doctorate with distinction, and works as a generalist across the medical sciences and biology, having consulted for dozens of clients. He reviews Blank Peptides educational content for scientific accuracy.
Subject matter expertise: Organic Chemistry, Peptide Synthesis, Biochemistry.
